Lotus eye hospital And Institute Limited has announced that its Board of Directors will convene on February 11, 2026, to review the company's quarterly financial performance. The meeting has been scheduled in accordance with regulatory requirements under SEBI (LODR) Regulations 2015.

Board Meeting Details

The primary agenda for the board meeting includes consideration of the unaudited standalone financial results for the quarter and year ended December 31st, 2025. The company has formally notified both major stock exchanges about this scheduled meeting.

Trading Window Restrictions

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Insiders, Lotus Eye Hospital has implemented trading window restrictions. The trading window will remain closed until the financial results are announced and will reopen from February 13, 2026 onwards.

Stock Exchange Communication

The company has sent formal intimation letters to both BSE Limited and National Stock Exchange of India Limited regarding the upcoming board meeting. The communication was signed by M Achuth Menon, Company Secretary & Compliance Officer, on January 30th, 2026.

The announcement follows standard corporate governance practices and ensures transparency in financial reporting. Investors and stakeholders will receive the Q3FY26 financial results following the board meeting scheduled for February 11, 2026.

Lotus eye hospital and Institute Limited has received a disclosure from promoter Sangeetha Sundaramoorthy regarding a proposed share acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction involves the acquisition of shares from fellow promoter Kavetha Sundaramoorthy through an inter-se transfer arrangement.

Transaction Details

The proposed acquisition involves significant changes in promoter shareholding structure. Key transaction parameters are outlined below:

The share purchase agreement was executed on June 2, 2025, establishing the framework for this promoter-to-promoter transfer. The transaction is structured under sub-clause 10(1)(a)(ii) of SEBI regulations, which provides exemption from mandatory open offer requirements for inter-se transfers between promoters.

Regulatory Compliance and Pricing

The acquisition price of Rs 70 per share is positioned favorably compared to market benchmarks. The 60-day volume weighted average market price stands at Rs 81.30, making the transaction price approximately 13.91% below the market average. This pricing structure ensures compliance with SEBI regulations requiring acquisition prices not to exceed 25% above the computed market price.

Sangeetha Sundaramoorthy has provided formal declarations confirming compliance with all applicable disclosure requirements under Chapter V of the Takeover Regulations, 2011. The acquirer has also confirmed that all conditions specified under regulation 10(1)(a) regarding exemptions have been duly satisfied.

Shareholding Impact

The transaction will result in a significant redistribution of promoter holdings within Lotus Eye Hospital and Institute Limited:

Post-transaction, Sangeetha Sundaramoorthy and persons acting in concert will hold 35.0084% of the company's total share capital, representing an increase of 6.8693 percentage points. Conversely, Kavetha Sundaramoorthy's shareholding will decrease by the same percentage, reducing her stake to 2.7456%.

Strategic Implications

This inter-se transfer represents a consolidation of promoter holdings, with Sangeetha Sundaramoorthy emerging as the dominant promoter stakeholder. The transaction maintains overall promoter control while redistributing ownership concentration within the promoter group. The structured approach through formal share purchase agreements and regulatory compliance demonstrates adherence to corporate governance standards and transparency requirements mandated by SEBI for substantial acquisitions.